In today's first round matchup of The Motley Fool Better-Buy Tournament, InvenSense squares off against GlaxoSmithKline in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each other as they make the case for their stocks, with the winner determined by you, the readers.
InvenSense (INVN) is the better buy today for two big reasons, according to Motley Fool analyst Dave Meier. First, more than 7 billion mobile devices will hit the market over the next five years. And the expectations for the wearables market are even larger. All of those devices will need sensors, and InvenSense will be there to supply them. The company designs accelerometers, gyroscopes, and microphones and packages them in various combinations with tiny processors, bringing incredible functionality to users. Management anticipates 25%-35% sales growth in 2014. Meier expects the stock price to respond in kind, making it the better buy today.
Motley Fool analyst Max Macaluso makes the case for GlaxoSmithKline (GSK 0.12%) to move to the next round. The major pharmaceutical company has pioneered a unique approach to research and development that has already started to pay off; last year, the company won FDA approval for melanoma drugs Tafinlar and Mekinist, and it has a number of experimental drugs in development.
Watch these analysts square off in the video below and then vote for a winner. Then check out the other companies in the Motley Fool Better-Buy Bracket.
This year's winning stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Cast your vote in the poll below the video!
